Search results
In RA Treatment, Don't Overlook Underlying CV Risks
Medscape· 5 days agoPatients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated...
India's Biocon posts Q4 profit fall as higher raw material costs bite
Reuters via Yahoo Finance· 5 days agoIndian biopharmaceutical company Biocon reported a decline in its fourth-quarter profit on Thursday, as soaring raw material costs overshadowed growth in its biosimilar business in key United ...
Why Is My Scalp Flaky? Exploring The Causes Of Dandruff And How It’s Treated
IFLScience· 3 days agoDandruff is a harmless – if irritating – condition that usually affects the skin of the scalp,...
Critics Say FDA's Use of Surrogate Markers Falling Short
Medscape· 4 days agoAs the FDA's use of surrogate endpoints in the drug approval process is increasing, researchers are...
If you suffer from anxiety or depression, these are the physical consequences you could suffer from
Hardwood Paroxysm· 5 days agoSuffering from psychological disorders is very common and increasing in the era in which we live....
Pain-Management Tips Are All Over TikTok. But What’s Legit?
Washingtonian· 6 days agoDoctors share their insights on trending advice on TikTok.
Dermata Therapeutics announces warrant exercise and new issuance By Investing.com
Investing.com· 4 days agoDermata Therapeutics, Inc. (NASDAQ:DRMA), a biotech firm engaged in skin disease treatments, has...
5 proposals for extracting water from the sea and air
Hardwood Paroxysm· 3 days agoAccording to data from the World Resources Institute, by 2050 One third of the world’s GDP will be exposed to water stress. The sea can be an inexhaustible source of water, and several initiatives ...
AbbVie (NYSE:ABBV) Now Covered by Cantor Fitzgerald
ETF DAILY NEWS· 2 days agoCantor Fitzgerald assumed coverage on shares of AbbVie (NYSE:ABBV – Get Free Report) in a research note issued to investors on Friday, MarketBeat.com reports. Cantor Fitzgerald’s price objective ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 21 hours agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
